Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
一项随机、开放标签的 II 期研究,旨在评估纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗高肿瘤突变负荷的晚期或转移性实体瘤患者的疗效。
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-008872
Schenker, Michael; Burotto, Mauricio; Richardet, Martin; Ciuleanu, Tudor-Eliade; Gonçalves, Anthony; Steeghs, Neeltje; Schoffski, Patrick; Ascierto, Paolo A; Maio, Michele; Lugowska, Iwona; Lupinacci, Lorena; Leary, Alexandra; Delord, Jean-Pierre; Grasselli, Julieta; Tan, David S P; Friedmann, Jennifer; Vuky, Jacqueline; Tschaika, Marina; Konduru, Somasekhar; Vemula, Sai Vikram; Slepetis, Ruta; Kollia, Georgia; Pacius, Misena; Duong, Quyen; Huang, Ning; Doshi, Parul; Baden, Jonathan; Di Nicola, Massimo